PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells.

Area of Science:

• Oncology
• Immunology
• Metabolic pathways

Background:

• Immunotherapies targeting programmed-cell-death-1 (PD1) and its ligand (PD-L1) show limited efficacy in most colorectal cancer (CRC) patients due to low mutational burden and lack of an inflamed tumor microenvironment.
• Peroxisome proliferator-activated receptor-gamma (PPARγ), a metabolic transcription factor, has been linked to immunotherapy response.
• Microsatellite stable (MSS) CRC tumors often do not respond to current immunotherapies.

Purpose of the Study:

• To investigate if PPARγ activation can enhance the efficacy of PD-L1 blockade in MSS CRC.
• To explore the mechanism by which PPARγ influences PD-L1 expression in CRC cells.
• To evaluate the therapeutic potential of combining PPARγ agonists with PD-L1 inhibitors for CRC treatment.

Main Methods:

• Treatment of human gastrointestinal cancer cell lines and patient-derived tumor organoids (PDOs) with PPARγ agonists.
• Analysis of PD-L1 mRNA and protein expression.
• Chromatin immunoprecipitation assays to assess PPARγ binding to the PD-L1 promoter.
• Co-culture experiments involving tumor cells, PD-L1 blocking antibodies, and lymphokine-activated killer (LAK) cells.

Main Results:

• PPARγ agonists significantly upregulated PD-L1 expression in cancer cell lines and MSS+ PDOs.
• PPARγ was shown to directly bind to response elements in the PD-L1 gene promoter, activating its transcription.
• Combined treatment with PPARγ agonists and PD-L1 blocking antibodies reduced tumor cell proliferation and viability in co-culture models.

Conclusions:

• PPARγ activation can induce PD-L1 expression on MSS CRC cells, making them more susceptible to PD-L1 blockade.
• Metabolic modulation via PPARγ agonists represents a promising strategy to enhance anti-tumor immune responses in CRC.
• This study proposes novel therapeutic combinations for treating MSS colorectal cancer.